Real-world results show sustained psoriasis improvement with tildrakizumab

Key takeaways:

• Body surface area and PGA scores were each reduced in patients treated with tildrakizumab.
• PASI 75, 90 and 100 were achieved by 87%, 56.5% and 32.6% of treated patients.

Tildrakizumab exhibited real-world efficacy and safety for long-term treatment of plaque psoriasis, according to a study.

“Plaque psoriasis, the most common type of psoriasis, is a chronic inflammatory skin disorder that requires life-long management,” Jayme Heim, MSN, FNP-BC, of West Michigan Dermatology, and colleagues wrote. “Moderate to severe plaque psoriasis typically requires systemic treatment, although topical treatments and phototherapy are also available.”

The FDA approved tildrakizumab, a humanized anti-interleukin-23 p19 monoclonal antibody, for moderate to severe psoriasis based on results of the phase 3 reSURFACE trials; however, long-term efficacy in a real-world setting had not been widely studied.

This phase 4, uncontrolled, open-label trial included 55 adult patients (mean age, 48.6 years; 94.6% white), of which 45 completed 64 weeks of treatment.

Patients received 100 mg of tildrakizumab at weeks 0 and 4 and then every 12 weeks through week 52. Of the 45 patients who were evaluated at week 64, 36 received all doses.

The mean plaque psoriasis body surface area was reduced by 83.1% from a mean of 14.5 ± 11.5 to 2.1 ± 3.6, whereas the mean static Physician Global Assessment was reduced by 67.6% from a mean of 3.2 ± 0.6 to 1 ± 1).

Mean PASI scores also showed significant decreases from the 11.6 score at baseline, including scores of 6.5 at week 4, 2.2 at week 16, 1.8 at week 28 and 1.6 at week 52 (P < .001 for all).

PASI 75 was achieved by 87% of patients, PASI 90 by 56.5% and PASI 100 by 32.6% at week 52.

Treatment-emergent adverse events occurred in 34 (61.8%) of enrolled patients; however, none of the events were determined to be related to treatment. The most common were psoriasis, hypertension and dermatitis.

“Tildrakizumab treatment results in improvement across multiple measures of disease severity in adult patients with moderate to severe plaque psoriasis in the real-world setting,” the authors wrote.